Skip to main content

Table 1 Patient and treatment characteristics versus DPD activity levels

From: DPD status and fluoropyrimidines-based treatment: high activity matters too

Variable Modality Low DPD activity (< 0.30 nmol/min/mg prot) High DPD activity (≥ 0.30 nmol/min/mg prot) Fisher-test
Age at FP-based treatment (NA = 0) Mean [SD] 64.22 [12.11] 64.38 [13.67] 0.95*
Sex (NA = 0)     0.17
  Female 67 (85.9%) 11 (14.1%)
  Male 44 (75.86%) 14 (24.14%)
Cancer location (NA = 0)     0.76
  Digestive 86 (81.9%) 19 (18.1%)
  Head and Neck 5 (71.43%) 2 (28.57%)
  Breast 20 (83.33%) 4 (16.67%)
Disease severity (NA = 0)    0.33
  Local disease 35 (87.5%) 5 (12.5%)
  Advanced disease 76 (79.17%) 20 (20.83%)
DPD prescription (NA = 0)     0.59
  Before FP start 89 (82.41%) 19 (17.59%)
  During FP Treatment 22 (78.57%) 6 (21.43%)
Other chemotherapy before FP (NA = 0)     0.61
  No 85 (82.52%) 18 (17.48%)
  Yes 26 (78.79%) 7 (21.21%)
FP-based treatment (NA = 0)     0.61
  Capecitabine 29 (76.32%) 9 (23.68%)
  5-FU 58 (82.86%) 12 (17.14%)
  Both alternatively 24 (85.71%) 4 (14.29%)
FP-based toxicity (NA = 4)     0.17
  No 57 (52.78%) 16 (69.57%)
  Yes 51 (47.22%) 7 (30.43%)
Surgery associated to FP (NA = 1)     0.31
  No 31 (88.57%) 4 (11.43%)
  Yes 79 (79%) 21 (21%)
Radiotherapy associated to FP (NA = 0)     0.65
  No 47 (79.66%) 12 (20.34%)
  Yes 64 (83.12%) 13 (16.88%)
Nb. of chemotherapy lines (NA = 1) Median [Min-Max] 1 [1–12] 2 [1–5] 0.26**
Nb. of FP cycles (NA = 0) Median [Min-Max] 7 [1–48] 9 [1–18] 0.39**
Observed complete response during FP treatment (NA = 6)    0.032
  No 35 (34.31%) 14 (60.87%)
  Yes 67 (65.69%) 9 (39.13%)
Any recurrence (NA = 0)     0.12
  No 52 (46.85%) 7 (28.0%)
  Yes 59 (53.15%) 18 (72.0%)
  1. NA not available data, FP Fluoropyrimidine, Fisher-test p-value Fisher exact test, * p-value Student-T test, ** p-value Wilcoxon test, SD Standard Deviation